Sipralexa

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sipralexa

Quick Facts

Property Description
Active ingredient Escitalopram (Escitalopram oxalate)
Form Film-coated tablet, oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Enhancing mood stability and emotional balance
Origin Synthetic, single-isomer compound (S-enantiomer)

What Type of Medicine is Sipralexa?

Sipralexa is defined as a prescription-only medicine and a psychotropic agent, belonging to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). This classification identifies it as a synthetic compound designed to modify specific chemical signaling pathways within the central nervous system. The SSRI class is recognized for its focused action on mood-regulating neurotransmitters. Sipralexa’s general purpose is to foster improved mood stability and emotional well-being, and it is administered exclusively via the oral route.

Escitalopram: Composition and Formulation

The action of Sipralexa is derived from its sole active ingredient, Escitalopram, which is chemically distinguished as the pure S-enantiomer. This synthetic compound represents a single-isomer approach, containing only the therapeutically active half of the older, racemic citalopram molecule. The chemical identity of the active ingredient is defined by its molecular structure. Escitalopram is formulated in two distinct dosage forms—a film-coated tablet and an oral solution—to facilitate administration.

How Does Escitalopram Relate to Serotonin?

Escitalopram exerts its effect through the selective inhibition of serotonin reuptake in the brain. This process involves the drug binding specifically to the serotonin transporter, thereby blocking the normal process by which nerve cells reclaim the neurotransmitter serotonin. This selective action increases the functional availability of serotonin, leading to enhanced serotonergic neurotransmission. This sustained availability of serotonin facilitates the rebalancing of chemical signals, which is the intended mechanism for promoting emotional regulation.

What side effects are possible with Sipralexa?

The official safety profile for escitalopram, the active ingredient in Sipralexa, is categorized by government regulatory agencies based on the frequency of observed reactions, which are often most prominent during the initial one or two weeks of therapy and typically decrease with continued treatment.

Frequency Classification of Adverse Effects

Adverse reactions are classified into frequency categories derived from clinical data. Very Common reactions, affecting one or more out of every ten people, include headache and nausea.

Classification System-Organ-Class Examples
Common (up to 1 in 10) Somnolence, Insomnia, Dry mouth, Fatigue, Increased sweating, Diarrhoea, Dizziness, Anxiety, Decreased libido, Ejaculation disorder.
Uncommon (up to 1 in 100) Tachycardia, Mydriasis (pupil dilation), Gastrointestinal haemorrhages, Urticaria (hives), Alopecia (hair loss), Agitation, Panic attack.

Serious Adverse Reactions and Safety Considerations

Regulatory documentation highlights several serious adverse reactions. The rare condition known as Serotonin Syndrome has been reported, especially with co-administration of other serotonergic agents. The label also notes the potential for cardiac risks, including QT interval prolongation and Ventricular Arrhythmia, such as torsade de pointes. The risk of suicidal thoughts and behavior is documented, particularly in children, adolescents, and young adults up to 24 years of age, emphasizing close observation during early treatment and dose changes. Other considerations include the risk of hyponatraemia (low blood sodium levels), activation of mania or hypomania, and the potential for abnormal bleeding or haemorrhage. Safety warnings also exist for specific populations; for instance, the drug is contraindicated in individuals with known congenital long QT syndrome.

Overdose and Emergency Response

Overdose: When to Seek Help

Sipralexa (escitalopram) overdose is a medical emergency. While many reported cases are associated with mild or no symptoms, severe outcomes, including fatalities, have been documented, particularly when the drug is taken with other substances.

Documented Overdose Presentations

Symptoms of an overdose may involve the central nervous system, cardiovascular system, and gastrointestinal tract. Specific manifestations that have been reported include:

  • CNS Effects: Dizziness, somnolence, convulsions (seizures), and coma.
  • Cardiovascular Effects: Hypotension (low blood pressure), tachycardia (rapid heart rate), and electrocardiogram (ECG) changes, including QT prolongation.
  • Other Symptoms: Nausea and vomiting.

Serotonin syndrome is a critical complication of overdose, which can lead to agitation, fever, rapid heart rate, confusion, and severe muscle stiffness.

Required Emergency Action

Immediate medical attention is required for any suspected overdose. If a victim has collapsed, has a seizure, or cannot be awakened, call emergency services immediately. Treatment for an overdose is symptomatic and supportive, as there is no specific antidote for escitalopram. Management focuses on monitoring for vital sign changes and cardiac abnormalities. The treating physician may consider procedures such as the administration of activated charcoal to reduce drug absorption, depending on the circumstances of the ingestion.

Therapeutic Uses of Sipralexa

Sipralexa is applied across domains where additional symptomatic support is needed to manage conditions characterized by significant emotional and functional strain. The medication is used in therapeutic domains and clinical contexts marked by temporary physiological imbalance and acute or disruptive symptom patterns.

It is commonly used across conditions presenting with acute episodes or recurrent manifestations and is relevant for conditions including Major Depressive Disorder (MDD) and several Anxiety and Fear Disorders. These include Generalized Anxiety Disorder (GAD), Panic Disorder (PD) with or without agoraphobia, Social Anxiety Disorder (SAD), and Obsessive-Compulsive Disorder (OCD).

Quick Fact: Symptomatic Support for Excessive Worry and Anhedonia

The medication helps address symptom clusters that may become intense or disruptive, such as persistent sadness, loss of interest (anhedonia), excessive, chronic worry, and symptoms related to intense fear and phobic avoidance. It contributes to improved comfort during periods of heightened symptoms, and may assist patients to cope more steadily with symptom fluctuations. “This medication provides supportive relief when symptoms become temporarily overwhelming, helping to manage symptoms to support stability in daily routines.”

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sipralexa — Official Regulatory Information

Sipralexa (escitalopram) is subject to strict eligibility rules based on official government regulatory documents, defining who can and who must not use the medicine.

Contraindications (Must NOT Use):

Classification Populations / Conditions
Absolute Known hypersensitivity to escitalopram, citalopram, or any component of the formulation.
Co-medication Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, or within 14 days of discontinuing an MAOI.
Cardiac Concomitant use with Pimozide and use in patients with known QT interval prolongation or congenital long QT syndrome.

Conditional or Restricted Use (Use with Caution):

  • Age: Use is permitted in adults; for Major Depressive Disorder, it is approved for patients 12 years of age and older. For Generalized Anxiety Disorder, it is approved for patients 7 years of age and older. Use in children younger than these specific ages is not established.
  • Organ Function: Patients with hepatic impairment or who are elderly are typically advised a lower maximum daily dose (e.g., 10 mg/day). Caution is advised for patients with severe renal impairment.
  • Clinical Status: Pregnancy and breastfeeding are typically listed under caution; the drug is generally not recommended unless the clinical need outweighs potential risks to the fetus or infant. Patients with a history of seizures, mania/bipolar disorder, or those at increased risk of bleeding require special medical consideration.

What should I know about interactions with other medicines?

Sipralexa (escitalopram) can interact with a range of other medications, supplements, and products, potentially increasing the risk of side effects or altering drug effectiveness. It is essential to inform your healthcare provider about all prescription, over-the-counter (OTC) medicines, and herbal supplements you are taking.

Contraindicated Combinations (Do Not Use)

  • Monoamine Oxidase Inhibitors (MAOIs): Combining Sipralexa with MAOIs (e.g., phenelzine, selegiline, tranylcypromine, linezolid, methylene blue) is strictly contraindicated. This combination can lead to Serotonin Syndrome, a serious condition. A washout period of at least two weeks is required when switching between Sipralexa and an MAOI.
  • Pimozide: Co-administration with the antipsychotic pimozide is not recommended due to an increased risk of QT prolongation (a heart rhythm disorder).

Increased Risk of Serotonin Syndrome

Use caution or avoid combining Sipralexa with other medicines that also increase serotonin levels. This includes other antidepressants (like SSRIs, SNRIs, TCAs), Tryptans (for migraines, e.g., sumatriptan), the opioid pain reliever Tramadol, and the herbal product St. John's wort.

Increased Risk of Bleeding

Sipralexa can increase the risk of bleeding. This risk is amplified when taken with other medications that affect blood clotting:

Interaction Type Examples of Affected Medicines
Anticoagulants (Blood Thinners) Warfarin, Apixaban, Rivaroxaban
Antiplatelet Drugs Aspirin, Clopidogrel
NSAIDs (Pain/Inflammation) Ibuprofen, Naproxen

Other Important Interactions

  • Medicines affecting heart rhythm (QT prolongation): Use with caution with certain antiarrhythmics (e.g., amiodarone, sotalol), some antipsychotics (e.g., thioridazine), and certain antibiotics (e.g., clarithromycin) as the risk of cardiac rhythm changes may be increased.
  • Alcohol: Avoid consuming alcohol, as it may worsen drowsiness and impair concentration associated with Sipralexa.

Mechanism of Action

How Sipralexa Works

Sipralexa's action is fundamentally based on its highly specific, dual-stage mechanism within the central nervous system, focused entirely on modulating the serotonin pathway.


Molecular Target: Selective SERT Inhibition

The mechanism begins with Escitalopram's precise molecular action as a Selective Serotonin Reuptake Inhibitor (SSRI). It binds with high affinity to the Serotonin Transporter (SERT) protein, immediately and effectively blocking the normal process of serotonin (5-HT) reabsorption. This targeted blockade leads to the prompt accumulation and increased functional availability of 5-HT within the neuronal synapse, initiating subsequent signaling changes.


⏳ Pathway Adaptation and Sustained Modulation

The sustained high levels of 5-HT trigger a critical time-dependent cascade: the desensitization of inhibitory 5-HT1A autoreceptors. This adaptive physiological change removes the "brake" on 5-HT release, resulting in a sustained, amplified serotonergic signal across relevant circuits. This alteration of neurotransmission dynamics facilitates the long-term modulation of activity within 5-HT sensitive CNS circuits, leading to a functional shift in neural activity patterns.

Dosage and Administration Information

Sipralexa (escitalopram) is administered orally once daily, either in the morning or evening, and may be taken with or without food. The medication should be taken at a consistent time each day to maintain a regular schedule.

Official Dosing and Administration

The recommended starting dose for most adult patients is 10 mg once daily. Depending on the condition being treated and patient response, this dose may be increased to a maximum of 20 mg once daily. Dosing adjustments must adhere to specific time intervals: for adults with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD), an increase to 20 mg should occur only after a minimum of one week of treatment at 10 mg.

Age Group / Condition Initial Daily Dose Titration Interval (to max 20 mg)
Adults (MDD/GAD) 10 mg ≥ 1 week
Adolescents (MDD, 12+ yrs) 10 mg ≥ 3 weeks
Elderly / Hepatic Impairment 10 mg Maximum recommended dose

Procedural and Missed Dose Instructions

If the medication is an oral solution, the bottle must be shaken well before each dose, and a proper measuring device should be used to ensure accuracy. Tablets should be swallowed whole. If a dose is missed, skip the missed dose and resume the regular schedule at the next designated time; a double dose should not be taken to compensate. When discontinuing treatment, a gradual dose reduction is recommended to minimize potential discontinuation symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Pharmacokinetic and Efficacy Studies

Research has explored changes to Drug A’s pharmacokinetic properties with the addition of Drug B, and the relationship of this change to measured changes in the severity and frequency of symptoms. Studies evaluated the time to onset of an effect and the duration of any observed change in clinical signs. Key findings analyzed data comparing the combination to Drug A alone in a variety of clinical settings, with researchers noting specific outcome measures.

Measured Parameter Study Type
Primary Outcome: Condition Y score was measured. Randomized Controlled Trials (RCTs)
Secondary Outcome: Time to maximum plasma concentration (T max) was measured. Pharmacokinetic Studies

Long-Term Safety and Tolerability

Clinical trials focused on the long-term administration of the drug combination. Small-scale observational studies also reported findings related to condition X. These trials also reported the observed adverse event profile during long-term use. Study results generally reported side effects as having been mild or moderate.


Meta-Analysis and Pooled Data

A large meta-analysis synthesized evidence regarding whether Drug B may modify the effect of Drug A, and findings suggested that changes in pharmacokinetic parameters were observed across different patient groups. The analysis included data from 12 randomized controlled trials (RCTs).

The studies described the observed risk of side effects. Limited comparative data regarding other treatments was analyzed. No clinical suitability or comparative statements are drawn from this data.

Frequently Asked Questions (FAQ)

Common questions about Sipralexa (FAQ)


Q: Does Sipralexa cause weight gain or weight loss?

Official product information notes that changes in appetite can occur with this medication. According to clinical trial data, this may sometimes manifest as either weight loss or weight gain.

Q: Will Sipralexa affect my sleep pattern?

Studies and regulatory documents indicate that Sipralexa can affect sleep. Insomnia (difficulty sleeping) and somnolence (drowsiness or sleepiness) are both listed as common side effects.

Q: Is it normal to feel a little more anxious when you first start taking Sipralexa?

Regulatory warnings mention that during the initial weeks of treatment, or after a dose change, some patients may experience a worsening of anxiety symptoms, agitation, or restlessness. This is why patients are monitored closely by a healthcare professional, especially during the initial treatment period.

Q: What if I experience unusual dreams or nightmares on Sipralexa?

Official regulatory documents list sleep disturbances, which can include the occurrence of intense or unusual dreams, as potential side effects of the medication.

Q: Does the effectiveness of Sipralexa decrease over time?

For treating Major Depressive Disorder, studies have demonstrated the benefit of maintenance treatment over several months or longer. Official guidance emphasizes that treating physicians should periodically re-evaluate the medication to determine its continued usefulness for a patient.

Q: Does taking Sipralexa require any specific blood tests or monitoring?

Close monitoring for changes in behavior, including suicidal thoughts, is a key part of the official safety information, especially during early treatment. If signs of unwanted effects like hyponatremia (abnormally low blood sodium levels) arise, blood tests may be conducted, as this is noted as a potential serious side effect.

Q: Does Sipralexa have an effect on blood pressure?

Although not listed as a common side effect, regulatory documents note that conditions such as Serotonin Syndrome or overdose may include symptoms like hypertension (high blood pressure). This is why the medication is always taken under medical supervision.

Q: Is the nausea from Sipralexa temporary?

According to official product information, adverse reactions like nausea are typically most frequent during the first one or two weeks of treatment. These symptoms commonly decrease in both intensity and frequency as treatment continues.

Q: Does Sipralexa interact with common cold or flu medications?

Caution is advised with many over-the-counter cold and flu products. For instance, medications that affect blood clotting, such as common NSAID pain relievers, or those that affect serotonin levels, like some cough suppressants (e.g., dextromethorphan), may require medical consideration due to potential interactions.

Q: Are patients required to avoid cheese or aged foods while taking Sipralexa (like with MAOIs)?

No tyramine-restricted diet is necessary while taking Sipralexa. This type of strict dietary restriction is only required for patients taking Monoamine Oxidase Inhibitors (MAOIs), which are strictly forbidden for use in combination with Sipralexa.

Q: What is the typical peak effect time after taking a single dose of Sipralexa?

Official pharmacokinetic data indicates that the drug is rapidly absorbed into the body. The maximum concentration in the blood is typically reached in approximately 3 to 4 hours after a single oral dose.

Q: Can Sipralexa cause changes in appetite?

Yes, regulatory documents list changes in appetite as potential side effects. These can include both a loss of appetite and, for some patients, an increased appetite.

Q: How quickly does Sipralexa start working after you begin taking it?

While the full, complete therapeutic effect may take several weeks to be achieved, official information notes that some patients may start to notice improvements in sleep, energy levels, or appetite within the first one to two weeks of starting treatment.

Q: How long do most people stay on Sipralexa treatment?

Treatment for conditions like Major Depressive Disorder (MDD) often requires sustained therapy for several months or longer to prevent relapse. The decision for continued use is made by the treating physician, who periodically re-evaluates the ongoing need for maintenance treatment.

Q: Can older adults safely take Sipralexa?

Sipralexa is approved for use in elderly patients, though this use requires special consideration. The recommended dose for older adults is typically a lower maximum daily dose (10 mg), and this group is noted to have an elevated risk for certain side effects, such as low blood sodium (hyponatremia).

Q: Is it better to take Sipralexa in the morning or at night?

The official instructions state the medication can be administered once daily, and this can be done in either the morning or the evening. It can be taken with or without food. Maintaining consistency in the timing of the dose is often emphasized.

Q: What are the most common side effects people experience when first starting Sipralexa?

Side effects are usually most frequent and noticeable during the first one or two weeks of treatment. The most common initial effects include headache and nausea, along with others like drowsiness, insomnia, and dry mouth.

Q: What is the typical timeframe for tapering off Sipralexa?

When discontinuing treatment, a gradual dose reduction is formally recommended to minimize potential discontinuation symptoms. This tapering process is determined and managed by a healthcare provider, and typically takes place over a period of several weeks or months.

Q: How soon after stopping Sipralexa are other medications safe to start?

A specific waiting period is required when switching to certain other drug classes. For instance, at least 7 days must pass after discontinuing Sipralexa before a patient can safely begin taking a Monoamine Oxidase Inhibitor (MAOI).

How should Sipralexa be stored and disposed of?

How to Store and Dispose of Escitalopram (Sipralexa)

The storage and disposal instructions for escitalopram are based on regulatory requirements to maintain product stability and ensure public safety.


Official Storage Conditions

Escitalopram must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from excess heat and moisture and should not be frozen.

Keep the medicine in its original container and ensure the container is tightly closed. For child safety, the product must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired escitalopram must be disposed of in accordance with local and federal requirements. The preferred method is using a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash, following FDA guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sipralexa found in:

A-Z Index: